Title
Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris.

Permalink
https://escholarship.org/uc/item/6wk399d6

Journal
Frontiers in Immunology, 9

ISSN
1664-3224

Authors
Amber, Kyle T
Valdebran, Manuel
Grando, Sergei A

Publication Date
2018

DOI
10.3389/fimmu.2018.01190

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris

Kyle T. Amber 1*, Manuel Valdebran 1 and Sergei A. Grando 1,2,3*

1 Department of Dermatology, University of California Irvine, Irvine, CA, United States, 2 Department of Dermatology, Institute for Immunology, University of California Irvine, Irvine, CA, United States, 3 Department of Biological Chemistry, Institute for Immunology, University of California Irvine, Irvine, CA, United States

Pemphigus vulgaris (PV) is a potentially life-threatening mucocutaneous autoimmune blistering disease. Patients develop non-healing erosions and blisters due to cell–cell detachment of keratinocytes (acantholysis), with subsequent suprabasal intraepidermal splitting. Identified almost 30 years ago, desmoglein-3 (Dsg3), a Ca\(^{2+}\)-dependent cell adhesion molecule belonging to the cadherin family, has been considered the “primary” autoantigen in PV. Proteomic studies have identified numerous autoantibodies in patients with PV that have known roles in the physiology and cell adhesion of keratinocytes. Antibodies to these autoantibodies include desmocollins 1 and 3, several muscarinic and nicotinic acetylcholine receptor subtypes, mitochondrial proteins, human leukocyte antigen molecules, thyroid peroxidase, and hSPCA1—the Ca\(^{2+}\)/Mn\(^{2+}\)-ATPase encoded by ATP2C1, which is mutated in Hailey–Hailey disease. Several studies have identified direct pathogenic roles of these proteins, or synergistic roles when combined with Dsg3. We review the role of these direct and indirect mechanisms of non-desmoglein autoantibodies in the pathogenesis of PV.

Keywords: pemphigus, autoantibodies, secretory pathway Ca\(^{2+}\) ATPase, ATP2C1, acantholysis, keratinocyte, acetylcholine

INTRODUCTION

Pemphigus vulgaris (PV) is a potentially life-threatening mucocutaneous autoimmune blistering disease. Patients develop non-healing erosions and blisters due to cell–cell detachment of keratinocytes (acantholysis), with subsequent suprabasal intraepidermal splitting. Identified more than 25 years ago, desmoglein-3 (Dsg3), a Ca\(^{2+}\)-dependent cell adhesion molecule belonging to the cadherin family, has been considered the “primary” autoantigen in PV.

While convincing evidence has supported the pathogenic role of anti-Dsg antibody-mediated acantholysis, there has been a shift in our understanding of the disease from steric hindrance by autoantibodies to modification of cell metabolism and signaling, and structural alterations in the desmosome affecting cell adhesion (1–3).

Abbreviations: ACh, acetylcholine; AChR, acetylcholine receptor; AMA, anti-mitochondrial antibodies; CytC, cytochrome c; DIF, direct immunofluorescence; Dsc, desmocollin; Dsg, desmoglein; FcRn, neonatal Fc receptor; HHD, Hailey–Hailey disease; HLA, human leukocyte antigen; mAChR, muscarinic acetylcholine receptor; mCaPV, mucocutaneous pemphigus vulgaris; MHC, major histocompatibility complex; mPTP, mitochondrial permeability transition pore; nAChR, nicotinic acetylcholine receptor; Pf, pemphigus foliaceus; PH, pemphigus herpetiformis; PKP3, plakophilin-3; PNP/PAMS, paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome; PV, pemphigus vulgaris; PVeg, pemphigus vegetans; PV IgG, IgG from pemphigus vulgaris patients; PX, pemphaxin.
Proteomic studies have identified numerous autoantibodies in patients with PV that have known roles in the physiology and cell adhesion of keratinocytes. These autoantibodies include desmocollins (Dsc) 1 and 3, several muscarinic and nicotinic acetylcholine receptor (nAChR) subtypes, mitochondrial proteins, human leukocyte antigen (HLA) molecules, thyroid peroxidase (TPO), and hSPCA1—the Ca\(^{2+}\)/Mn\(^{2+}\)-ATPase encoded by ATP2C1, which is mutated in Hailey–Hailey disease (HHD).

The presence of numerous potentially pathogenic autoantibodies in pemphigus points toward a need to understand these non-Dsg antibodies. While several of the most prevalent non-Dsg autoantibodies have been characterized regarding their effect on keratinocyte biology, a majority of identified autoantibodies remain poorly understood. We review the direct and indirect pathogenic mechanisms of non-Dsg autoantibodies in PV.

**MAJOR DEFINED AUTOANTIGENS**

**Desmocollins**

Desmocollins (Dsc) and Dsgs are two specialized Ca\(^{2+}\)-dependent cadherin subfamilies that provide structure to the desmosomes (4). On the cell surface, Dsc and Dsg bind to each other, providing support, and mediating connections between intermediate filaments of neighboring cells (5, 6). In addition, this cadherin complex forms an anchor for keratin intermediate filaments which attach to the inner cytoplasmic surface (6).

Desmocollins play an important role in cell-to-cell adhesion. This role was demonstrated by Spindler et al. (7) through the application of monoclonal antibodies against extracellular domains of Dsc3 in human skin model which resulted in intraepidermal blister formation. They also provided evidence of homophilic and heterophilic trans-interaction of Dsc3 with Dsg1. Their data showed that Dsg-1 IgG antibodies reduce the adhesion of Dsc-3 to the surface of keratinocytes, possibly by targeting the Dsc3/Dsg1 binding on keratinocyte cell surface (7).

Previously, IgA autoantibodies to Dsc1 were identified in subcorneal pustular dermatosis (8). However, various reports of IgG autoantibodies against the three different Dsc have been found in paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome (PNP/PAMS), PV, pemphigus foliaceus (PF), pemphigus vegetans (PVeg), and pemphigus herpetiformis (PH) (9).

In a study of a large cohort of pemphigus patients, autoantibodies to Dsc 1 and 3 were present in 44% of patients, with only 7% in matched controls (10). Ishii et al. reported their findings related to the detection of anti-Dsc antibodies in a series of 164 pemphigus cases. Anti-Dsc antibodies were found in 3 of 22 PV cases (13%) and 3 of 18 PF cases (18%). By contrast, 53 of 79 PNP/PAMS cases (67%) demonstrated anti-Dsc 1–3 antibodies. Specifically, Dsc3 antibodies were detected in roughly 60% of the cases, Dsc 2 in 37%, and Dsc 3 in 16.5% of cases. In PH and PVeg, around 40% of sera showed strong reactivity with Dsc1–3 (11).

Dettmann et al. studied serum reactivity with Dsc 1, 2, and 3 serum autoantibodies in various groups of patients with pemphigus. In their first cohort consisting of 102 PV patients with oral lesions with positive direct immunofluorescence (DIF) and the presence of anti-Dsg3 IgG, no antibodies were found against Dsc 1, 2, and 3. The second cohort was composed of 24 patients with oral lesions but no detectable Dsg3 autoantibodies; therein IgG antibodies against Dsc 3 were found in one case. The third cohort composed of 23 patients with PNP/PAMS mostly reactive against anti-Dsg3 and envoplakin, from whom anti-Dsc 2 and anti-Dsc 3 IgG autoantibodies were identified in two patients, respectively (9). A fourth cohort consisting of sera from 749 patients of the International Autoimmune Bullous Diseases Study Group was also analyzed for reactivity with epitopes of Dsc. Of these patients, 333 were diagnosed with pemphigus. Investigators found 14 (4%) Dsc reactive cases; 3 were from patients with PNP/PAMS, 2 from patients with PVeg, 2 of 14 sera were from PV patients in whom no Dsg 1 or 3 reactivity was found. Three reactive cases of PF showed Dsc 1-specific IgG. Of 5 Dsg3-negative sera, 333 (40%) showed reactivity with Dsc 1. Thus, testing for autoantibodies against Dscs was only recommended in patients with atypical pemphigus (9).

**hSPCA1**

The ATP2C1 gene codes for a magnesium-dependent enzyme that catalyzes the hydrolysis of Ca\(^{2+}\)-transport ATP. This secretory pathway Ca\(^{2+}\) ATPase pump is expressed in the Golgi apparatus (GA) which is involved in the transport of calcium and manganese ions from the cytosol to the lumen of the GA. Mutations in ATP2C1 results in depletion of Ca\(^{2+}\) stores in the GA with increased Ca\(^{2+}\) in the cytosol (12). Low Ca\(^{2+}\) concentration in the GA could impair posttranslational processing of important desmosomal proteins such as Dsg and Dsc. As a result, acantholysis develops. These mutations have been found in HHD (12, 13).

Clinical and pathological similarities between HHD and PV exist. Clinically, vesicle and bulla formation may be present in early lesions of HHD. However, features of established lesions include eroded scaly plaques in symmetrical and intertriginous distribution, commonly in axillae, groin, neck, inframammary fold, and perineum (14). On the other hand, features of PV include flaccid blisters and erosions on mucosa and sometimes also skin. Histologically, in PV, suprabasal acantholysis is present with intraepidermal bulla formation and a tombstone pattern of the remaining cells of the basal layer. Although acantholysis is also present in HHD, it involves all epidermal layers resembling the dilapidated brick wall (14). Invariably, DIF is negative in HHD.

Over 125 pathogenic mutations through the ATP2C1 gene have been described in HHD (15, 16). Approximately 20% are nonsense mutations, 30% are frame-shift mutations with premature termination codons, and 28% are missense mutations (17). Investigators suggest that haploinsufficiency is the mechanism of dominant inheritance observed in this entity (18).

Autoantibodies against hSPCA1 are seen in 43% of patients with PV compared to 8% in matched controls (OR = 8.51) (10). Given the similarities in clinical phenotype and role of cell disadhesion in both of these diseases, it is tempting to suspect that anti-hSPCA1 autoantibodies have an active role in PV. To date, however, there have been no studies assessing the pathogenic role of these autoantibodies.

**Cholinergic Receptors**

The human epidermis has an elaborate non-neuronal cholinergic system composed of an axis that involves keratinocyte...
Acetylcholine (ACh) enzymes involved in ACh synthesis and degradation, and nicotinic and muscarinic acetylcholine receptors (AChRs) (19). Keratinocyte ACh plays a role in the regulation of cell–cell and cell–matrix adhesion. This mechanism is accomplished through AChR signaling. These receptors have a regulatory effect by activation or inhibition of kinase cascades. Resulting outcome will lead to either upregulation or downregulation of the expression of cell adhesion molecules such as cadherins and integrins (19).

Muscarinic acetylcholine receptors (mAChRs) are single-subunit transmembrane glycoproteins composed of five receptor subtypes (M₁–M₅). Odd-numbered mAChRs bind to pertussis toxin-insensitive G proteins stimulating phospholipase C enzymes that hydrolyze phosphatidylinositol 4,5-bisphosphate, yielding the second messenger molecules inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol which in turn control intracellular levels of Ca²⁺ and protein kinase C activity, respectively. Even-numbered mAChR subtypes couple to pertussis toxin-sensitive G proteins ultimately leading to inhibition of adenyl cyclase, and weakly stimulating phospholipase C; they also rectify K⁺ channels, and augment arachidonic acid release (19). In vitro experiments have shown that mAChR activation may prevent, stop, and reverse acantholysis mediated by pemphigus antibodies (20). Autoantibodies against mAChRs have been identified in the serum of 85–100% of pemphigus patients (21, 22). Lakshmi et al. prospectively evaluated the disease severity of 45 patients with pemphigus who were followed up at baseline, 3 months, and 15 months. They collected sera from these patients to assess the titers of antibodies against Dsg1/Dsg3 and anti-M3 mAChR to correlate them with disease severity and response to therapy. They found that antibody titers correlated significantly with disease activity and that anti-M3 mAChR antibodies were present in all cases (22).

Nicotinic acetylcholine receptors are members of the superfamily of ligand-gated ion channel proteins, mediating Na⁺ and Ca²⁺ influx and K⁺ efflux. These receptors are not only present on the surface of keratinocytes but also on the mitochondrial outer membrane (23). Mitochondrial-nAChRs inhibit mitochondrial permeability transition pore (mPTP) opening, restraining cytochrome c (CytC) release, thereby preventing apoptosis (24). IgG from patients with PV bind to several mitochondrial-nAChR subtypes (α3, α5, α7, α9, α10, β2, and β4), resulting in swelling of mitochondria, rupture of outer membrane, and release of CytC caused by mPTP opening. Moreover, CytC induces apoptosome formation with activation of caspase-9 with subsequent induction of apoptosis (25).

Pemphaxin (PX) is a 75-kDa annexin also known as annexin 31 or ANXA9 (26) which was discovered by screening of keratinocyte λgt11 cDNA expression library with PV IgG antibodies. PX acts as an AChR with dual muscarinic and nicotinic pharmacology. In vitro studies demonstrated that anti-PX antibodies induced acantholysis in keratinocyte monolayers; confirmation was done with immunofluorescence studies showing positivity in a net-like pattern. In vivo experiments demonstrated that while adsorption of anti-PX autoantibody abolished acantholytic activity of PV IgG fraction, adding it back to the preabsorbed fraction restored the acantholytic activity of PV IgG fraction, although anti-PX autoantibody alone did not cause clinically evident skin blisters (27). This finding indicates that PV results from synergistic action of several antibodies to different self-antigens, including AChRs (28). Simultaneous and synergistic action of PV IgGs against the cell membrane and mitochondrial-nAChRs inactivates adhesion molecules and opening of mPTP. Affected keratinocytes shrink and detach from neighboring cells. Therein, antibodies to desmosomal components prevent keratinocyte from re-attachment making keratinocyte detachment irreversible (29).

### Anti-Mitochondrial Proteins

Anti-mitochondrial antibodies (AMA) play an important role in the pathogenesis of PV as they can trigger the intrinsic apoptotic pathway. Adsorption of AMA prevents acantholysis (30). Autoantibodies against numerous mitochondrial antigens are seen in patients with PV, as summarized in Table 1. Other studies evaluating AMA in patients with pemphigus included that by Marchenko et al., which found AMA in 100% (6/6) of sera of patients with PV when studying penetration of PV IgG into the subcellular mitochondrial fraction (30). Experiments conducted by Chernyavsky et al. (25) found AMA against different subunits of mitochondrial ACh receptors in 100% (5/5) sera from patients who had anti-nAChR antibodies.

Anti-mitochondrial antibodies bind mitochondrial proteins eliciting the opening of the mPMP which cause massive swelling of mitochondria, rupture of outer membrane, release of Cytc, and subsequent activation of caspase-9 (31). In so doing, AMA can complement pro-acantholytic actions of other types.

### Table 1

| Antigen | Symbol | Incidence in PV (%) | Incidence in controls (%) | OR |
|---------|--------|---------------------|--------------------------|----|
| Mitochondrial processing peptidase beta subunit | PMPCB | 31 | 4 | 8.47 |
| Cytochrome b6 outer mitochondrial membrane isofrom precursor | CYBB | 19 | 1 | 13.07 |
| Carnitine O-palmitoyltransferase I, mitochondrial muscle isoform | CPT1B | 18 | 5 | 3.51 |
| Peptidase (mitochondrial processing) alpha | PMPCA | 16 | 4 | 3.75 |
| Mitochondrial import inner membrane translocase subunit TIM13 B | TIMM13 | 16 | 4 | 4.50 |
| Carnitine O-palmitoyltransferase I, mitochondrial liver isoform | CPT1A | 13 | 4 | 3.05 |
| Mitochondrial uncoupling protein 2 (UCP20) | UCP20 | 10 | 5 | 2.02 |
| Solute carrier family 25 (mitochondrial carrier; citrate transporter, member 5) | SLC25A5 | 10 | 4 | 2.27 |
| Solute carrier family 25 (mitochondrial carrier; peroxisomal membrane protein) member 17 | SLC25A5 | 8 | 1 | 5.75 |
| Mitochondrial intermediate peptidase | MIPEP | 7 | 1 | 9.93 |
| Mitochondrial import inner membrane translocase subunit | TIMM22 | 6 | 1 | 3.92 |

Frontiers in Immunology | www.frontiersin.org | June 2018 | Volume 9 | Article 1190 | 3
of non-Dsg antibodies launching a downstream signaling event involving Src, epidermal growth factor receptor kinase, p38 mitogen-activated protein kinase (p38MAPK), and c-Jun N-terminal kinase (30).

Chen et al. (29) demonstrated that PV IgGs including AMA couple with neonatal Fc receptor (FcRn) on the cell membrane. The PV IgGs–FcRn complex allows the entrance of AMA to the keratinocyte. Once in the cytosol, they dissociate and are trafficked to the mitochondria where they trigger proapoptotic events with subsequent Cytc release and activation of caspase-9 (25, 30). These events correlate with the shrinkage of basal keratinocytes seen in histologic sections (29).

Upon recovery, new desmosomes are extended toward neighboring keratinocytes; however, anti-Dsg antibodies prevent bonding of new desmosomes due to steric hindrance, thereby acantholysis becomes an irreversible process (29). The term “apoptolysis” has been introduced to denote these apoptotic and acantholytic events (30).

Overexpression of suppression of tumorigenicity 18 gene (ST18) in keratinocytes of predisposed individuals appears to increase susceptibility of cells to apoptosis and immune dysregulation (32–34). Interestingly, ST18 is overexpressed in PV non-lesional skin when compared with the skin of healthy individuals, indicating a possible predisposition to pemphigus (32). A variant in the promoter region drives increased gene transcription in a p53/p63-dependent manner. This polymorphism, however, appears to be most associated with PV arising in Jewish and Egyptian patients, rather than German, or Chinese (32, 35). Sarig et al. did, however, note an increase of ST18 in patients with psoriasis. Thus, it unclear whether ST18 overexpression simply is associated with inflammatory processes.

**Thyroid Peroxide Antibodies**

Thyroid peroxidase (TPO), originally described as thyroid microsomal antigen, is a member of the thyroid autoantigens which includes thyroglobulin and thyroid-stimulating hormone receptor (36). TPO is a glycoprotein present on the apical surface of thyroid follicular cells (36); it is involved in the synthesis of T3 and T4, catalyzing several steps in the process (37). Approximately 85–90% of patients with chronic thyroiditis have anti-TPO antibodies (38); therefore, these antibodies are considered to be the hallmark of autoimmune thyroid disease (ATD), particularly, Hashimoto's thyroiditis, postpartum thyroiditis, and Grave's disease (37).

Several studies have documented the association between PV and the presence of anti-TPO antibodies as it is summarized in Table 2. The mean percentage of pemphigus patient with anti-TPO antibodies among all these studies was 19% (3.6–40%), which is well above the standard incidence of anti-TPO autoantibodies. Nevertheless, larger prospective multi-centric studies are needed to further characterize this association.

The link between thyroid and skin development and homeostasis has been well documented (47–49). This relationship correlates with the ability of thyroid hormones to bind nuclear receptors with consequent effects on proliferation of keratinocytes and fibroblasts (50, 51). However, the role of thyroid proteins in cell-to-cell adhesion remains poorly understood (51).

**TABLE 2 | Current studies on the incidence of thyroid autoantibodies and thyroid disease in patients with pemphigus.**

| Study                        | Country | Patients | Incidence |
|------------------------------|---------|----------|-----------|
| Pitoia et al. (39)           | Argentina | PV (n = 15) | Anti-TPO 6 (40%) |
|                              |         |          | Hashimoto thyroiditis 1 (6.6%) |
| Michailidou et al. (40)      | Greece  | PV (n = 129) | Incidence of Thyroid disease 2 (2.6%) |
| Ansar et al. (41)            | Iran    | PV (n = 22) | Anti-TPO 5 (22%) |
| Daneshpazhooh et al. (42)    | Iran    | PV (n = 75) | Anti-TPO 12 (16%) |
| Leshem et al. (43)           | Israel  | PV and PF (n = 110) | Anti-TPO 4 (3.6%) |
| Kavala et al. (44)           | Turkey  | PV (n = 80) | Altered thyroid function test and anti-thyroid Ab 13 (16%) |
|                              |         |          | Anti-TPO 6 (8%) |
|                              |         |          | Anti-Tg 2 (2.5%) |
|                              |         |          | Primary thyroid disease (PTD) 13 (16%) |
|                              |         |          | Hashimoto thyroiditis 7 (9%) |
| Ameri et al. (45)            | Italy   | PV (n = 25) | Anti-TPO 6 (24%) |
| Parameswaran et al. (46)     | USA     | PV (n = 230) | Group database 23 (10%) |
|                              |         |          | Online survey 16 (9.36%) |
|                              |         |          | IPPF registry 36 (9.16%) |

PV, pemphigus vulgaris; anti-TPO, anti-thyroid peroxidase; anti-Tg, anti-thyroglobulin; TSH, thyroid-stimulating hormone; IPPF, International Pemphigus and Pemphigoid Foundation; ATD, autoimmune thyroid disease.

**Plakophilin 3**

Plakophilin 3 is a member of the armadillo family of proteins; this protein has an important role in the generation of a stable desmosome due to its multiple interactions with several proteins such as desmosomal cadherins, Dsg1, Dsg3, desmoplakin, plakoglobin, and epithelial keratin 18 (52, 53).

Autoreactivity against plakophilin-3 (PKP3) has been demonstrated by Lambert et al. in five PNP/PAMS (100%) sera and in one PV (25%) serum in a series that evaluated sera from five PNP, four PV, two PF, five bullous pemphigoid (BP), one cicatricial pemphigoid, and one linear IgA dermatosis (53). In a large study of PV patients using proteomic technique, 43% of PV patients had autoantibodies targeting plakophilin 3, compared with 7% of matched controls (OR = 6.56) (10).

Preliminary experiments done by Sklyarova et al. have demonstrated that mice deficient in PKP3 show alteration and rearrangement of desmosomes in the epidermis and hair follicles (54). While desmosomes and adherens junctions were significantly altered, compensatory changes in junctional proteins were seen, with upregulation of desmoplakin, plakophilin 1 and 2, E-cadherin, and β-catenin. These mice were also prone to dermatitis. Thus, while it appears unlikely that loss of PKP3 can
lead to the clinical phenotype in pemphigus, it is one key to a dense network of proteins that stabilize desmosomes.

**E-Cadherin**

E-cadherins along with P-cadherin are the classical cadherins forming adherens junctions, which in conjunction with desmosomes mediate cell-to-cell adhesion (55). Overexpression of E-cadherin has been observed as a result of disruption of desmosomes by PV autoantibodies. E-cadherin partially compensates for loss of cell cohesion, rescuing the cell but also attenuating activation of p38MAPK. E-cadherin is required to assemble Dsg3 into desmosomes (55).

Oliveira et al. and Evangelista et al. have demonstrated antibodies targeting E-cadherin in sera of pemphigus patients (56, 57). One study identified autoantibodies in 78% of mucocutaneous pemphigus vulgaris (mcPV) (n = 62) and 33% (n = 18) of those with mucosal involvement. Moderate correlation was found between the index values of E-cadherin and Dsg1 antigen/antibody, but no correlation with Dsg3; this finding suggested that antibodies against E-cadherin might cross-react with Dsg1 (or vice versa) (57). Similar findings were reported by Evangelista et al. who demonstrated anti-E-cadherin antibodies in 100% of sera of patients with pemphigus foliaceus (n = 13) and fogo selvagem (n = 15); autoantibodies were observed in 79% of those with mcPV and none of the mucosal-type PV (n = 7) (56).

More recent proteomic studies of patients with PV demonstrate autoantibodies against E-cadherin in 31% of pemphigus patients compared with 7% of healthy controls (OR = 4.29) (10). Thus, while further pathogenicity studies are needed, the already published data suggests an important synergistic role of E-cadherin autoantibodies in the pathogenesis of pemphigus.

**Plakoglobin**

Plakoglobin is a member of the Armadillo family of adhesion and signaling proteins. It has a key role in the organization of desmosomes (58, 59). The highly conserved intracytoplasmic–cadherin-like segment of Dsgs is required for direct binding of Dsgs to plakoglobin (60). Silencing of plakoglobin results in p38MAPK-dependent cell disadhesion in cultured keratinocytes. Plakoglobin additionally regulates levels of Dsg3 (61). Interestingly, inhibition of p38MAPK can prevent PV IgG-induced blistering (62). In PV, there is an accumulation of c-Myc, due to a decrease in plakoglobin-mediated suppression of c-Myc (63). Plakoglobin is a principle effector of PV IgG downstream signaling (64–66). Plakoglobin can additionally regulate the promoters of Dsc2 and Dsc3 (67). While a compensatory increase in beta-catenin can be seen in the setting of plakoglobin silencing, it is insufficient for maintaining normal levels of plakophilin-1 or desmoplakin in the desmosomal plaque (68).

Plakoglobin is precipitated from sera of PV and PF patients, linked to Dsgs (69). It is internalized in combination with Dsg3 and PV IgG, resulting in retraction of keratin filaments (70). PV IgG may also promote separation of Dsg3 and plakoglobin (71). This is consistent with immunohistochemical studies in PV, in which plakoglobin staining was displaced toward the nucleus in comparison to healthy control (72).

Larger studies of autoantibodies in patients with PV demonstrated that 26% of patients carried autoantibodies against junctional plakoglobin, compared with 5% of controls (OR = 5.15) (10). Ishii et al. likewise described a patient with PNP/PAMS who had immunoreactivity against plakoglobin (73). Whether these anti-plakoglobin autoantibodies participate in the plakoglobin-Dsg3 dissociation remains to be determined.

**FceRI**

Human immunoglobulin E (IgE) molecules bind with very high affinity to receptors on the surface of basophils and mast cells. As a result, mast cells release histamine, leukotrienes, prostaglandins, and cytokines (74). Basophils and mast cells can be activated by cross-linking of IgE interacting with antigens (direct anaphylaxis) or by antibodies directed against Fce chain of IgE, or against the epitopes of α chain of FceRI or anti-IgG acting on IgG–IgE complexes bound to FceRI (74).

Tissue specific or systemic autoimmunity might lower the threshold of immunocompetent cells to recognize FceRI. For this reason, Fiebiger et al. (75) in their study on anti-FceRIα autoantibodies in chronic urticaria, included sera from patients with systemic and skin-specific autoimmune diseases including systemic lupus erythematosus, dermatomyositis, BP, and PV. Interestingly, anti-FceRIα antibodies were found in all groups. As opposed to chronic urticaria, antibodies from the autoimmune cutaneous diseases group lacked complement-activation properties, potentially limiting the activation of basophils and subsequent histamine release (75). Sera from 28 PV patients were analyzed by ELISA, of which 39% were positive for anti-FceRIα antibodies. Pronounced IgG reactivity against Western-blotted recombinant soluble FceRIα was found in sera of 2 PV patients. Particularly, IgG2 and IgG4 subtypes were found in these patients (75).

The significance of the anti-FceRIα antibodies in pemphigus remains unclear.

**Other Autoantibodies**

While the above discussed non-Dsg autoantibodies target known participants in cell disadhesion and autoimmunity, numerous other autoantibodies have been detected in patients with pemphigus (10). A better understanding of these and other non-Dsg antibodies will provide significant insight into the pathogenesis of pemphigus.

**HLA AS A LINK BETWEEN DIFFERENT IMPLICATED AUTOANTIGENS**

The HLA region is located on chromosome 6, present only in humans coding for the major histocompatibility complex (MHC) genes. MHC class I genes are known as HLA-A, HLA-B, and HLA-C; coding for proteins present on the surface of almost all cells. MHC class II genes are located within the HLA-D region on chromosome 6 which contains three subregions: DP, DQ, and DR. Each subregion has one expressed chain gene.

Oliveira et al. and Evangelista et al. have demonstrated autoantibodies targeting E-cadherin in sera of pemphigus patients (56, 57). One study identified autoantibodies in 78% of mucocutaneous pemphigus vulgaris (mcPV) (n = 62) and 33% (n = 18) of those with mucosal involvement. Moderate correlation was found between the index values of E-cadherin and Dsg1 antigen/antibody, but no correlation with Dsg3; this finding suggested that antibodies against E-cadherin might cross-react with Dsg1 (or vice versa) (57). Similar findings were reported by Evangelista et al. who demonstrated anti-E-cadherin antibodies in 100% of sera of patients with pemphigus foliaceus (n = 13) and fogo selvagem (n = 15); autoantibodies were observed in 79% of those with mcPV and none of the mucosal-type PV (n = 7) (56).

More recent proteomic studies of patients with PV demonstrate autoantibodies against E-cadherin in 31% of pemphigus patients compared with 7% of healthy controls (OR = 4.29) (10). Thus, while further pathogenicity studies are needed, the already published data suggests an important synergistic role of E-cadherin autoantibodies in the pathogenesis of pemphigus.
subtypes have demonstrated an association with the DRB1*0402, DRB1*1401, DRB1*1404, DRB1*1454, DQB1*0503, and DQB1*0302 alleles. In fact, more than 95% of PV patients carry one of the following alleles: DRB1*0402 or DQB1*0503 (2, 77, 78). Particularly, these last two alleles are strongly associated with the Ashkenazi Jewish population (79). PV has been associated with HLA class I including those with HLA-A3, A10, A26, B15, B35, B38, B44, and B60; however, their significance is yet to be elucidated (77). Susceptibility to PF has been linked to the presence of DR4, DR14, and DR1, although no single DR4 or DR14 allele was dated (77). Susceptibility to PF has been linked to the presence of B38, B44, and B60; however, their significance is yet to be elucidated.

High-risk HLA alleles can efficiently accommodate autoantigen-derived peptides, thus eliciting a T-cell-mediated response (78). At the same time, B-cells can be activated by anti-desmosomal CD4 T effector cells.

In contrast to antigen presentation, MHC II autoantibodies can be seen in up to 45% of patients with PV compared 7% in healthy controls (OR = 6.22), with autoantibodies against numerous MHC I and MHC II molecules (10). The functional role of these autoantibodies remains unclear.

Sajda et al. studied a panel of different autoantibodies present in sera of 40 PV patients, 20 healthy relatives, and 20 unrelated controls. Among these antibodies, they identified five which were more significantly associated with PV including Dsg3, mAChR3, mAChR4, mAChR5, and TPO. Of particular interest, non-Dsg autoantibodies in sera of healthy relatives of patients with PV were also seen. Subsequently, they performed HLA analysis clustering the patients into those who had presence or absence of PV-associated HLA alleles DRB1*0402 and/or DQB1*0503. Interestingly, most healthy relatives who presented with these alleles had similar antibody profiles to that of active pemphigus patients, whereas relatives who were negative for the risk alleles had antibody profiles similar to those of unrelated controls (81). Further findings revealed that autoantibody levels on HLA+ and HLA− relatives were comparable, thus implying that further genetic and environmental factors may lead to clinical pathology and remains to be studied (81). These data highlight the importance of HLA as a driver for the breakdown of self-tolerance and the specificity of the autoimmune response.

CONCLUSION

The pathogenesis of pemphigus is a complex process involving autoantibodies against numerous structural and metabolic proteins that regulate keratinocyte adhesion and survival. Several of these autoantibodies have been confirmed to have a pathogenic role in pemphigus, by altering the desmosomal plaque, synergistically complementing classic anti-Dsg autoantibody action, or altering mitochondrial physiology. In light of the hundreds of autoantibodies present in patients with PV, only few remain characterized. Thus, significant work is needed to determine the pathogenicity of these autoantibodies.

AUTHOR CONTRIBUTIONS

Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: KA, MV, and SG.

REFERENCES

1. Nguyen VT, Arredondo J, Chernyavsky Al, Kitajima Y, Pittelkow M, Grando SA. Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. J Biol Chem (2004) 279(3):2135–46. doi:10.1074/jbc.M309000200
2. Di Zenzo G, Amber KT, Sayar BS, Muller BJ, Borradori L. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol (2016) 38(1):57–74. doi:10.1007/s00281-015-0541-1
3. Spindler V, Eming R, Schmidt E, Amagai M, Grando S, Jonkman MF, et al. Mechanisms causing loss of keratinocyte cohesion in pemphigus. J Invest Dermatol (2017) 138(1):32–7. doi:10.1016/j.jid.2016.06.022
4. Chitave NA, Trojanovsky SM. Direct Ca2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J Cell Biol (1997) 138(1):193–201. doi:10.1083/jcb.138.1.193
5. Garrod DR, Merritt AJ, Nie Z. Desmosomal cadherins. Curr Opin Cell Biol (2002) 14(5):537–45. doi:10.1016/S0955-0674(02)00366-6
6. Kitajima Y. New insights into desmosome regulation and pemphigus blistering as a desmosome-remodeling disease. Kaohsiung J Med Sci (2013) 29(1):1–13. doi:10.1016/j.kjms.2012.08.001
7. Spindler V, Heupel WM, Efthymiadis A, Schmidt E, Eming R, Rankl C, et al. Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus. J Biol Chem (2009) 284(44):30556–64. doi:10.1074/jbc.M109.024810
8. Hashimoto T, Kiyokawa C, Mori O, Miyasato M, Chidgey MA, Garrod DR, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol (1997) 109(2):127–31. doi:10.1111/1523-1747.ep12319025
9. Dettmann IM, Kruger S, Fuhrmann T, Rentzsch K, Karl I, Probst C, et al. Routine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical pemphigus. Exp Dermatol (2017) 26(12):1267–70. doi:10.1111/exd.13409
10. Kalantari-Dehaghi M, Anhalt GJ, Camilleri MJ, Chernyavsky Al, Chun S, Felgner PL, et al. Pemphigus vulgaris autoantibody profiling by proteomic technique. PLoS One (2013) 8(3):e57587. doi:10.1371/journal.pone.0057587
11. Ishii N, Teye K, Fukuda S, Uehara R, Hachiya T, Koga H, et al. Anti-desmocollin autoantibodies in nonclassical pemphigus. Br J Dermatol (2015) 173(1):59–68. doi:10.1111/bjd.13711
12. Zhang F, Yan X, Jiang D, Tian H, Wang C, Yu L. Eight novel mutations of ATP2C1 identified in 17 Chinese families with Hailey-Hailey disease. Derma-tology (2007) 215(4):277–83. doi:10.1159/000107620
13. Bradini W, Abou Hassan OK, Saadeh D, Abbas O, Ballout F, Kibbi AG, et al. Identification of several mutations in ATP2C1 in Lebanese families: insight into the pathogenesis of Hailey-Hailey disease. PLoS One (2015) 10(2):e0115530. doi:10.1371/journal.pone.0115530
14. Chiaravalloti A, Payette M. Hailey-Hailey disease and review of management. J Drugs Dermatol (2014) 13(10):1254–7.
15. Shi BJ, Xiao S, Zhang Z, Lu J, Xue M, Jiang Y, et al. The ATP2C1 gene in Hailey-Hailey disease patients: one novel deletion and one novel splicing mutation. J Eur Acad Dermatol Venereol (2015) 29(12):2495–7. doi:10.1111/jdv.12398
16. Micaroni M, Gia-chetti G, Plebani R, Xiao GG, Federici L. ATP2C1 gene mutations in Hailey-Hailey disease and possible roles of SPCA1 isoforms in membrane trafficking. Cell Death Dis (2016) 7(6):e2259. doi:10.1038/cddis.2016.147
17. Szegi R, Kellermayer R. Autosomal-dominant calcium ATPase disorders. J Invest Dermatol (2006) 126(11):2370–6. doi:10.1038/sj.jid.5700447
Chernyavsky A, Sugurwa K, Kimura U, Takamori K, Akiyama M. A novel ATP2C1 early truncation mutation suggests haploinsufficiency as a pathogenic mechanism in a patient with Hailey-Hailey disease. Acta Derm Venereol (2013) 93(6):719–20. doi:10.2340/00015555-1551

Grando SA. Cholinergic control of epidermal cohesion. Exp Dermatol (2006) 15(4):265–82. doi:10.1111/j.1600-6705.2006.00410.x

Grando SA, Dahl MV. Activation of keratinocyte muscarinic acetylcholine receptors reverses pemphigus acantholysis. J Eur Acad Dermatol Venereol (1993) 2(2):72–86. doi:10.1111/j.1468-3038.1993.tb0016.x

Vu TN, Lee TX, Ndoye A, Shultz LD, Pettelkov MR, Dahl MV, et al. The pathophysiological significance of non-desmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol (1998) 134(8):971–80.

Lakshmi MJ, Jaisankar TJ, Rajappa M, Thappa DM, Chandrashekar L, Divyapriya D, et al. Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus. J Am Acad Dermatol (2017) 76(5):895–902. doi:10.1016/j.jaad.2016.11.039

Kalashnyk OM, Gergalova GL, Komisarenko SV, Skok MV. Intracellular localization of nicotinic acetylcholine receptors in human cell lines. Life Sci (2012) 91(21–22):1033–7. doi:10.1016/j.lfs.2012.02.005

Lykhum O, Gergalova G, Koval L, Zhmak M, Komisarenko S, Skok M. Muscaronidemia express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int J Biochem Cell Biol (2014) 53:246–52. doi:10.1016/j.biocel.2014.05.030

Chernyavsky A, Chen Y, Wang PH, Grando SA. Pemphigus vulgaris autoantibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptosis. Int Immunopharmacol (2015) 29(1):76–80. doi:10.1016/j.intimp.2015.04.046

Lanza A, Cirillo N, Femiano F, Gomboa F. How does acantholysis occur in pemphigus vulgaris: a critical review. J Cutan Pathol (2006) 33(6):401–12. doi:10.1034/j.1600-0528.2006.00523.x

Lykhum O, Gergalova G, Koval L, Zhmak M, Komisarenko S, Skok M. Muscaronidemia express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int J Biochem Cell Biol (2014) 53:246–52. doi:10.1016/j.biocel.2014.05.030

Chernyavsky A, Chen Y, Wang PH, Grando SA. Pemphigus vulgaris autoantibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptosis. Int Immunopharmacol (2015) 29(1):76–80. doi:10.1016/j.intimp.2015.04.046

Chen Y, Chernyavsky A, Webber RJ, Grando SA, Wang PH. Critical role of the neonatal Fc receptor (FcRn) in the pathogenic action of antimitochondrial autoantibodies synergizing with anti-desmoglein autoantibodies in pemphigus vulgaris. J Biol Chem (2015) 290(39):23826–37. doi:10.1074/jbc.M115.680861

Chernyavsky A, Chernyavskaya AI, Arredondo J, Gindi V, Grando SA. Anti-mitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology. J Biol Chem (2010) 285(6):3695–704. doi:10.1074/jbc.M109.081570

Arredondo J, Chernyavskaya AI, Karaozun A, Grando SA. Novel mechanisms of target cell death and survival and of therapeutic action of IVL in pemphigus. Am J Pathol (2005) 167(6):1531–44. doi:10.1016/S0002-9440(10)61239-4

Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, et al. Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. J Invest Dermatol (2015) 140(1):93–101. doi:10.1038/jid.2014.166

Bonne S, Gilbert B, Hatzfeld M, Chen X, Green KJ, van Roy F. Defining desmosomal plakophilin-3 interactions. J Cell Biol (2003) 161(2):403–12. doi:10.1083/jcb.20030306

Lambert J, Brarke S, van Roy F, Pas HH, Bonne S, De Schepper S. Serum plakophilin-3 autoantibody in paraneoplastic pemphigus. Br J Dermatol (2010) 163(3):630–2. doi:10.1111/j.1365-2133.2010.09845.x

Sklyarova T, Bonne S, D’Hooge R, Goossens S, De Rycke R, et al. Prevalence of thyroid autoimmunity in patients with pemphigus vulgaris. J Invest Dermatol (2013) 130(1):93–101. doi:10.1038/jid.2010.180

Yin T, Getiosis S, Caldelari R, Godsel LM, Kowalczyk AP, Muller EJ, et al. Mechanisms of plakoglobin-dependent adhesion: desmosome-specific functions in assembly and regulation by epidermal growth factor receptor. J Biol Chem (2008) 283(48):32015–24. doi:10.1074/jbc.M800890200

Yin T, Getiosis S, Caldelari R, Kowalczyk AP, Muller EJ, Jones JC, et al. Plakoglobin suppresses keratinocyte motility through both cell-cell adhesion dependent and -independent mechanisms. Proc Natl Acad Sci U S A (2005) 102(15):5420–5. doi:10.1073/pnas.0501676102
60. Roh JY, Stanley JR. Plakoglobin binding by human Dsg3 (pemphigus vulgaris antigen) in keratinocytes requires the cadherin-like intracytoplasmic segment. J Invest Dermatol (1995) 105(4):720–4. doi:10.1111/1523-1747.ep12600963

61. Spindler V, Dehner C, Hubner S, Waschke J. Plakoglobin but not desmoplakin regulates keratinocyte cohesion via modulation of p38MAPK signaling. J Invest Dermatol (2014) 134(6):1655–64. doi:10.1038/jid.2014.21

62. Egu DT, Walter E, Spindler V, Waschke J. Inhibition of p38MAPK signaling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis. Br J Dermatol (2017) 177(6):1612–8. doi:10.1111/bjd.15721

63. Williamson L, Raess NA, Caldelari R, Zakher A, de Bruin A, Posthaus H, et al. Plakoglobin as a key suppressor of c-Myc in the skin. EMBO J (2006) 25(14):3298–309. doi:10.1038/sj.emboj.7601224

64. Muller E, Caldelari R, de Bruin A, Baumann D, Bierkamp C, Balmer VV, et al. Plakoglobin in pemphigus vulgaris: a central role for the armadillo protein plakoglobin. J Invest Dermatol (2000) 115(2):332. doi:10.1046/j.1523-1747.2000.00abs-2.x

65. Caldelari R, de Bruin A, Baumann D, Suter MM, Hunziker T, Wyder M, et al. Plakoglobin-dependent disruption of the desmosomal plaque in pemphigus vulgaris. Exp Dermatol (2007) 16(6):468–75. doi:10.1111/j.1600-0625.2007.00557.x

66. Muller E, Caldelari R, De Bruin A, Baumann D, Bierkamp C, Balmer VV, et al. Pathogenesis in pemphigus vulgaris: a central role for the armadillo protein plakoglobin. J Invest Dermatol (2000) 115(2):332. doi:10.1046/j.1523-1747.2000.00abs-2.x

67. Tokonzaba E, Chen J, Cheng X, Den Z, Ganeshan R, Muller EJ, et al. Plakoglobin as a regulator of desmocollin gene expression. J Invest Dermatol (2013) 133(12):2732–40. doi:10.1038/jid.2013.220

68. Acehan D, Petzold C, Gumper I, Sabatini DD, Muller EJ, Cowin P, et al. Plakoglobin is required for effective intermediate filament anchorage to desmosomes. J Invest Dermatol (2008) 128(11):2665–75. doi:10.1038/jid.2008.141

69. Korman NJ, Eyre RW, Klaus-Kovtun V, Stanley JR. Demonstration of an armadillo region in human epidermal basal cells. J Cell Biol (1995) 133(1):427–37. doi:10.1083/jcb.133.1.427

70. Tokonzaba E, Chen J, Cheng X, Den Z, Ganeshan R, Muller EL, et al. Plakoglobin as a regulator of desmocollin gene expression. J Invest Dermatol (2013) 133(12):2732–40. doi:10.1038/jid.2013.220

71. Aoyama Y, Owada MK, Kitajima Y. A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur J Immunol (1999) 29(7):2233–40. doi:10.1002/(SICI)1521-4141(199907)29:7<2233::AID-IMMU2233>3.0.CO;2-4

72. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Farronato G, et al. Strict correlation between uPAR and plakoglobin expression in pemphigus vulgaris. J Cutan Pathol (2002) 29(9):540–8. doi:10.1034/j.1600-0560.2002.290906.x

73. Ishii M, Izumi J, Fujiwara H, Ito M, Hamada M. Immunoblotting detection of gamma-catenin (plakoglobin) antibody in the serum of a patient with paraneoplastic pemphigus. Br J Dermatol (2001) 144(2):377–9. doi:10.1046/j.1365-2133.2001.04031.x

74. Marone G, Spadaro G, Palumbo C, Condorelli G. The anti-IgE/anti-FcepsilonRIalpha autoantibody network in allergic and autoimmune diseases. Clin Exp Allergy (1999) 29(1):1–7. doi:10.1038/sj.cex.93022201.441.x

75. Feiliger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest (1998) 101(1):243–51. doi:10.1172/JCI511

76. Todd JA, Acha-Orbea H, Bell JJ, Chao N, Fronk E, Jacob CO, et al. A molecular basis for MHClassII–associated autoimmunity. Science (1998) 280(4365):1503–9.

77. Sinha AA. The genetics of pemphigus. Dermatol Clin (2011) 29(3):381–91. doi:10.1016/j.det.2011.03.020

78. Amber KT, Staropoli P, Shimam MI, Elgart GW, Hertl M. Auto reactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol (2013) 22(11):699–704. doi:10.1111/exd.12229

79. Slomov E, Loewenthal R, Goldberg I, Korostishovsky M, Brenner S, Gazit E. Pemphigus vulgaris in Jewish patients is associated with HLA-A region genes: mapping by microsatellite markers. Hum Immunol (2003) 64(8):771–9. doi:10.1016/j.humimm.2003.09.008

80. Tron F, Gilbert D, Mouquet H, Joly P, Drouot L, Makni S, et al. Genetic factors in pemphigus. J Autoimmun (2005) 24(4):319–28. doi:10.1016/j.jaut.2005.03.006

81. Sajda T, Hazleton J, Patel M, Seiffert-Sinha K, Steinman L, Robinson W, et al. Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus. Proc Natl Acad Sci U S A (2016) 113(7):1859–64. doi:10.1073/pnas.1525448113

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Amber, Valdebran and Grando. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.